2-氯脱氧腺苷是晚期惰性非霍奇金淋巴瘤的一种有效的补救疗法。
2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.
作者信息
Hoffman M, Tallman M S, Hakimian D, Janson D, Hogan D, Variakogis D, Kuzel T, Gordon L I, Rai K
机构信息
Long Island Jewish Medical Center, Albert Einstein College of Medicine, New Hyde Park, NY 11042.
出版信息
J Clin Oncol. 1994 Apr;12(4):788-92. doi: 10.1200/JCO.1994.12.4.788.
PURPOSE
To determine the response rate to 2-chlorodeoxyadenosine (2-CdA; cladribine) in patients with advanced indolent non-Hodgkin's lymphoma (NHL) who fail to respond to or progress after a response to standard chemotherapy drugs.
PATIENTS AND METHODS
Twenty-one patients were treated with at least one cycle of 2-CdA 0.1 mg/kg/d by continuous infusion for 5 or 7 days.
RESULTS
The overall response rate (complete response [CR] and partial response [PR]) was nine of 21 patients (43%; 95% confidence interval, 22% to 64%). Unmaintained durable responses (longest follow-up, 29+ months) have been observed. The treatment was well tolerated by all patients. The major toxicity was related to myelosuppression (predominantly neutropenia) and immunosuppression with infection.
CONCLUSION
The purine analog 2-CdA is an active salvage therapy in pretreated patients with indolent NHL, and deserves further assessment in untreated patients and in combination with other chemotherapy agents.
目的
确定对于标准化疗药物治疗无效或在治疗有反应后病情进展的晚期惰性非霍奇金淋巴瘤（NHL）患者，2-氯脱氧腺苷（2-CdA；克拉屈滨）的缓解率。
患者与方法
21例患者接受至少一个周期的2-CdA治疗，剂量为0.1mg/kg/d，持续静脉输注5或7天。
结果
21例患者中总体缓解率（完全缓解[CR]和部分缓解[PR]）为9例（43%；95%置信区间，22%至64%）。观察到未维持的持久缓解（最长随访时间为29+个月）。所有患者对该治疗耐受性良好。主要毒性与骨髓抑制（主要是中性粒细胞减少）和感染相关的免疫抑制有关。
结论
嘌呤类似物2-CdA是预处理的惰性NHL患者的一种有效的挽救疗法，值得在未治疗的患者中以及与其他化疗药物联合使用时进行进一步评估。
Zotero 插件